Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma - Trial NCT03704298
Access comprehensive clinical trial information for NCT03704298 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kite, A Gilead Company and is currently Not yet recruiting. The study focuses on Relapsed/Refractory Large B-cell Lymphoma. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kite, A Gilead Company
Gilead Sciences
Timeline & Enrollment
Phase 1
Nov 20, 2018
Jun 01, 2022
Primary Outcome
For Phase 1: Percentage of Participants Experiencing Adverse Events defined as Dose Limiting Toxicities (DLTs),For Phase 2: Complete Response Rate
Summary
The primary objectives of this study are:
 
 Phase 1: To evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and
 to identify the most appropriate dose and timing of utomilumab to carry forward into Phase 2
 
 Phase 2: To evaluate the efficacy of axicabtagene ciloleucel and utomilumab in participants
 with refractory large B-cell lymphoma
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03704298
Non-Device Trial